Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Amarin Reports First Quarter 2011 Results

May 10, 2011 By Bio-Medicine.Org

DUBLIN and MYSTIC, Conn., May 10, 2011 /PRNewswire/ — Amarin
Corporation plc (NASDAQ:
AMRN
), a clinical-stage biopharmaceutical company focused on
cardiovascular disease, today reported financial results for the
quarter ended March 31, 2011 (Q1 2011). The Company also provided
an update on its business progress related to the development
program of AMR101, its lead product candidate. AMR101 is being
developed as a next generation lipid modification drug with an
initial clinical focus on the treatment of elevated triglyceride
levels, which is associated with the increased risk of developing
cardiovascular disease as well as being a component of certain
other metabolic disorders, such as diabetes and obesity.

Q1 2011 Financial UpdateAmarin’s cash and cash equivalents as
of March 31, 2011 totaled $129.5 million. This cash balance
includes $98.7 million in net cash proceeds received by Amarin in a
January 2011 public offering of 13.8 million ADSs (American
Depository Shares, each representing one ordinary share) at a price
of $7.60 per ADS. Additionally, during the three months ended
March 31, 2011, the Company issued 994,749 ADSs as a result of
the exercise of stock options and 4,557,364 ADSs as a result of the
exercise of warrants, resulting in net proceeds to the Company of
$1.7 million and $6.5 million, respectively.

Amarin had approximately 126.2 million ADSs, 29.4 million
warrants and 10.4 million stock options outstanding at March 31,
2011.

During the three months ended March 31, 2011, net cash
outflows from operating activities were $8.8 million compared to
$7.8 million for the same period in 2010. During Q1 2011, the
Company’s total operating expenses were $7.2 million compared to
$7.4 million in the same period of the prior year.  This
reduction was a result of lower research and development costs,
reflecting the timing of clinical trial cos

‘/>”/>

SOURCE

Related Articles Read More >

TE Connectivity opens global medical device prototyping center in Ireland
Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech